Complete Filing Data
Acrivon Therapeutics, Inc. reported Stockholders Equity of $112.52 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Acrivon Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$77.9M | -$80.6M | -$60.4M | -$31.2M | -$16.2M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$336.0K | $530.0K | $12.0K | -$95.0K | |
| Other Nonoperating Income Expense | -$270.0K | -$558.0K | -$322.0K | $1.5M | $21.0K |
| Operating Income Loss | -$84.1M | -$89.2M | -$67.1M | -$32.7M | -$16.2M |
| Operating Expenses | $84.1M | $89.2M | $67.1M | $32.7M | $16.2M |
| Nonoperating Income Expense | $6.2M | $8.6M | $6.7M | $1.5M | -$59.0K |
| Comprehensive Income Net Of Tax | -$78.2M | -$80.0M | -$60.4M | -$31.3M | |
| Research And Development Expense | $60.0M | $64.0M | $46.0M | $23.9M | |
| General And Administrative Expense | $24.1M | $25.2M | $21.1M | $8.7M | |
| Interest Income Expense Nonoperating Net | $6.5M | $9.2M | $7.0M | ||
| Other Comprehensive Income Loss Tax | -$31.3M | -$16.2M | |||
| Net Income Loss And Comprehensive Income Loss | -$31.2M | -$16.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$18.2M | -$21.0M | -$19.7M | -$22.4M | -$18.8M | -$16.5M | -$14.5M | -$13.9M | -$12.8M | -$9.2M | -$5.8M | -$7.2M | -$2.4M | -$2.5M | -$6.9M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $6.0K | -$177.0K | -$164.0K | $801.0K | $51.0K | $13.0K | $125.0K | -$436.0K | $104.0K | -$133.0K | |||||
| Other Nonoperating Income Expense | -$53.0K | -$87.0K | -$14.0K | $1.0K | -$55.0K | -$264.0K | -$97.0K | -$164.0K | -$170.0K | $377.0K | $105.0K | -$8.0K | -$3.0K | ||
| Operating Income Loss | -$19.7M | -$22.6M | -$21.7M | -$25.1M | -$21.4M | -$17.7M | -$16.1M | -$15.5M | -$14.4M | -$9.6M | -$5.9M | -$7.2M | -$2.7M | ||
| Operating Expenses | $19.7M | $22.6M | $21.7M | $25.1M | $21.4M | $17.7M | $16.1M | $15.5M | $14.4M | $9.6M | $5.9M | $7.2M | $2.7M | ||
| Nonoperating Income Expense | $1.5M | $1.6M | $2.0M | $2.7M | $2.6M | $1.2M | $1.7M | $1.6M | $1.6M | $377.0K | $105.0K | -$8.0K | $231.0K | ||
| Comprehensive Income Net Of Tax | -$18.2M | -$21.2M | -$19.8M | -$21.6M | -$18.7M | -$16.5M | -$14.3M | -$14.4M | -$12.7M | -$9.3M | |||||
| Research And Development Expense | $13.6M | $16.2M | $15.4M | $18.9M | $15.0M | $11.5M | $10.3M | $10.5M | $9.8M | ||||||
| General And Administrative Expense | $6.0M | $6.5M | $6.2M | $6.3M | $6.4M | $6.2M | $5.9M | $5.0M | $4.6M | ||||||
| Interest Income Expense Nonoperating Net | $1.5M | $1.7M | $2.0M | $2.7M | $2.7M | $1.4M | $1.8M | $1.8M | $1.8M | ||||||
| Other Comprehensive Income Loss Tax | -$14.4M | -$12.7M | -$9.3M | -$5.8M | -$7.2M | -$2.4M | |||||||||
| Net Income Loss And Comprehensive Income Loss | -$9.2M | -$2.4M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $112.5M | $176.8M | $121.2M | $170.5M | -$23.8M | -$8.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $41.7M | $40.0M | $36.4M | $29.9M | $100.0M | $2.0M |
| Cash And Cash Equivalents At Carrying Value | $41.5M | $39.8M | $36.0M | $29.5M | $99.6M | |
| Retained Earnings Accumulated Deficit | -$274.9M | -$197.0M | -$116.4M | -$56.0M | -$24.9M | |
| Restricted Cash Noncurrent | $203.0K | $198.0K | $414.0K | $388.0K | $388.0K | |
| Restricted Cash | $203.0K | $198.0K | $414.0K | $388.0K | $388.0K | |
| Property Plant And Equipment Net | $4.9M | $4.5M | $3.5M | $2.1M | $290.0K | |
| Prepaid Expense And Other Assets Current | $1.9M | $2.1M | $2.2M | $4.3M | $805.0K | |
| Operating Lease Right Of Use Asset | $2.5M | $3.6M | $4.4M | $4.8M | $5.5M | |
| Operating Lease Liability Noncurrent | $1.5M | $2.6M | $3.8M | $4.2M | $5.0M | |
| Operating Lease Liability Current | $1.2M | $1.1M | $877.0K | $726.0K | $664.0K | |
| Liabilities Current | $15.7M | $17.2M | $13.3M | $6.5M | $2.9M | |
| Liabilities And Stockholders Equity | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M | |
| Liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M | |
| Common Stock Value | $31.0K | $31.0K | $23.0K | $22.0K | $2.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.7M | $3.6M | $6.5M | -$70.1M | $98.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $41.7M | $40.0M | $36.4M | $29.9M | $100.0M | |
| Assets Current | $120.4M | $181.6M | $129.7M | $132.1M | $100.4M | |
| Assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M | |
| Accrued Liabilities And Other Liabilities | $12.2M | $15.4M | $7.4M | $4.9M | $1.3M | |
| Accounts Payable Current | $2.3M | $758.0K | $5.0M | $904.0K | $964.0K | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $111.0K | $447.0K | -$83.0K | -$95.0K | ||
| Short Term Investments | $77.1M | $139.7M | $91.4M | $98.2M | ||
| Accretion Amortization Of Discounts And Premiums Investments | $437.0K | $3.8M | $3.3M | $698.0K | ||
| Non Cash Lease Expense | $778.0K | $731.0K | $795.0K | |||
| Long Term Investments | $5.1M | $41.9M | ||||
| Other Assets Noncurrent | $1.7M | $1.6M | $251.0K | |||
| Non Cash Operating Lease Expense | $1.0M | $932.0K | $778.0K | |||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $56.0K | $437.0K | $6.2M | |||
| Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses And Other Current Liabilities | ||||||
| Deferred Offering Costs Noncurrent | ||||||
| Deferred Offering Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities | $85.0K | $866.0K | ||||
| Purchases Of Property And Equipment Included In Accounts Payable | $17.0K | $635.0K | $30.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $128.6M | $143.0M | $160.4M | $196.9M | $216.1M | $108.0M | $138.1M | $149.2M | $160.5M | -$45.6M | -$36.6M | -$31.0M | -$19.8M | -$17.4M | -$14.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $35.6M | $42.1M | $39.4M | $43.6M | $46.4M | $25.0M | $30.3M | $38.5M | $27.9M | $32.5M | $84.2M | $91.2M | $4.0M | |||
| Cash And Cash Equivalents At Carrying Value | $35.4M | $41.9M | $39.2M | $43.4M | $46.0M | $24.6M | $29.9M | $38.1M | $27.5M | $32.1M | $83.9M | $90.8M | $3.6M | |||
| Retained Earnings Accumulated Deficit | -$255.9M | -$237.7M | -$216.7M | -$174.1M | -$151.7M | -$132.9M | -$97.2M | -$82.7M | -$116.4M | -$47.1M | ||||||
| Restricted Cash Noncurrent | $202.0K | $201.0K | $198.0K | $196.0K | $421.0K | $417.0K | $411.0K | $408.0K | $388.0K | $388.0K | ||||||
| Restricted Cash | $202.0K | $201.0K | $198.0K | $196.0K | $421.0K | $417.0K | $411.0K | $408.0K | $388.0K | $388.0K | $388.0K | $388.0K | $388.0K | |||
| Property Plant And Equipment Net | $5.2M | $5.1M | $4.7M | $4.7M | $3.5M | $3.4M | $2.0M | $2.0M | $2.0M | $2.2M | ||||||
| Prepaid Expense And Other Assets Current | $1.1M | $989.0K | $1.7M | $1.5M | $1.8M | $2.2M | $2.4M | $2.3M | $3.8M | $1.8M | ||||||
| Operating Lease Right Of Use Asset | $2.8M | $3.1M | $3.3M | $3.8M | $4.0M | $4.2M | $4.2M | $4.4M | $4.6M | $5.0M | ||||||
| Operating Lease Liability Noncurrent | $1.8M | $2.1M | $2.4M | $3.0M | $3.2M | $3.5M | $3.6M | $3.8M | $4.0M | $4.4M | ||||||
| Operating Lease Liability Current | $1.2M | $1.1M | $1.1M | $1.0M | $978.0K | $944.0K | $776.0K | $753.0K | $740.0K | $717.0K | ||||||
| Liabilities Current | $14.9M | $13.4M | $13.6M | $14.8M | $11.3M | $9.0M | $9.3M | $7.0M | $5.7M | $6.4M | ||||||
| Liabilities And Stockholders Equity | $145.3M | $158.6M | $176.3M | $214.7M | $230.6M | $120.5M | $151.1M | $160.0M | $170.2M | $87.7M | ||||||
| Liabilities | $16.7M | $15.5M | $16.0M | $17.8M | $14.5M | $12.5M | $12.9M | $10.9M | $9.7M | $10.8M | ||||||
| Common Stock Value | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $23.0K | $22.0K | $22.0K | $22.0K | $2.0K | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$664.0K | -$11.4M | -$2.0M | -$8.8M | ||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $35.6M | $42.1M | $39.4M | $43.6M | $46.4M | $25.0M | $30.3M | $38.5M | $27.9M | $32.5M | $84.2M | $91.2M | $4.0M | |||
| Assets Current | $130.4M | $138.4M | $151.3M | $189.0M | $182.4M | $112.1M | $144.5M | $153.3M | $124.0M | $78.7M | ||||||
| Assets | $145.3M | $158.6M | $176.3M | $214.7M | $230.6M | $120.5M | $151.1M | $160.0M | $170.2M | $87.7M | ||||||
| Accrued Liabilities And Other Liabilities | $12.7M | $11.1M | $8.8M | $12.3M | $9.0M | $6.0M | $7.0M | $5.0M | $3.6M | $3.7M | ||||||
| Accounts Payable Current | $996.0K | $1.2M | $3.7M | $1.5M | $1.3M | $2.1M | $1.5M | $1.3M | $1.4M | $2.0M | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $112.0K | $106.0K | $283.0K | $782.0K | -$19.0K | -$70.0K | -$302.0K | -$427.0K | $9.0K | -$133.0K | ||||||
| Short Term Investments | $93.8M | $95.5M | $110.5M | $144.0M | $134.5M | $85.4M | $112.2M | $112.9M | $92.7M | |||||||
| Accretion Amortization Of Discounts And Premiums Investments | $360.0K | $577.0K | $1.1M | |||||||||||||
| Non Cash Lease Expense | $224.0K | $191.0K | $178.0K | |||||||||||||
| Long Term Investments | $5.1M | $10.2M | $15.2M | $15.4M | $39.9M | $39.3M | ||||||||||
| Other Assets Noncurrent | $1.6M | $1.6M | $1.6M | $1.2M | ||||||||||||
| Non Cash Operating Lease Expense | $248.0K | $224.0K | ||||||||||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | ||||||||||||||||
| Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses And Other Current Liabilities | $485.0K | $47.0K | ||||||||||||||
| Deferred Offering Costs Noncurrent | $468.0K | $468.0K | $348.0K | $251.0K | ||||||||||||
| Deferred Offering Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities | $97.0K | |||||||||||||||
| Purchases Of Property And Equipment Included In Accounts Payable |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $14.7M | $14.3M | $11.6M | $2.2M | $497.0K |
| Share Based Compensation | $14.7M | $14.3M | $11.6M | $2.2M | $497.0K |
| Payments To Acquire Property Plant And Equipment | $1.7M | $2.8M | $1.3M | $2.2M | $238.0K |
| Net Cash Provided By Used In Operating Activities | -$63.7M | -$65.7M | -$42.6M | -$30.1M | -$14.0M |
| Net Cash Provided By Used In Investing Activities | $66.1M | -$51.8M | $50.7M | -$141.7M | -$238.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$190.0K | -$237.0K | -$2.1M | $3.5M | $764.0K |
| Increase Decrease In Operating Lease Liability | -$936.0K | -$1.1M | -$754.0K | -$667.0K | -$572.0K |
| Increase Decrease In Accounts Payable | $1.5M | -$3.6M | $3.6M | -$245.0K | $798.0K |
| Net Cash Provided By Used In Financing Activities | -$749.0K | $121.0M | -$1.6M | $101.7M | $112.2M |
| Proceeds From Stock Options Exercised | $1.0K | $90.0K | $775.0K | $24.0K | $1.0K |
| Proceeds From Sale And Maturity Of Available For Sale Securities | $149.5M | $153.9M | $108.5M | $10.7M | |
| Payments To Acquire Available For Sale Securities Debt | $81.7M | $202.9M | $56.5M | $150.2M | |
| Increase Decrease In Accrued Expense And Other Liabilities | -$3.4M | $8.0M | $3.2M | $2.9M | $866.0K |
| Payments Related To Tax Withholding For Share Based Compensation | $750.0K | $2.5M | $1.3M | ||
| Payments Of Stock Issuance Costs | $6.5M | $1.0M | $2.8M | ||
| Proceeds From Issuance Of Private Placement | $70.0M | $4.7M | |||
| Proceeds From Issuance Of Warrants | $60.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $3.9M | $3.9M | $3.8M | $3.7M | $3.6M | $3.3M | $3.2M | $2.7M | $2.6M | $267.0K | $233.0K | $40.0K | $27.0K | $27.0K | $139.0K |
| Share Based Compensation | $3.8M | $3.3M | $2.6M | $40.0K | |||||||||||
| Payments To Acquire Property Plant And Equipment | $58.0K | $815.0K | $25.0K | $415.0K | |||||||||||
| Net Cash Provided By Used In Operating Activities | -$19.5M | -$17.1M | -$11.4M | -$8.4M | |||||||||||
| Net Cash Provided By Used In Investing Activities | $19.2M | $5.9M | $9.3M | -$415.0K | |||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$466.0K | -$140.0K | -$593.0K | $884.0K | |||||||||||
| Increase Decrease In Operating Lease Liability | -$131.0K | -$199.0K | -$175.0K | -$156.0K | |||||||||||
| Increase Decrease In Accounts Payable | $2.8M | -$2.3M | $470.0K | -$95.0K | |||||||||||
| Net Cash Provided By Used In Financing Activities | -$343.0K | -$172.0K | |||||||||||||
| Proceeds From Stock Options Exercised | $1.0K | $79.0K | |||||||||||||
| Proceeds From Sale And Maturity Of Available For Sale Securities | $39.5M | $35.0M | $26.3M | ||||||||||||
| Payments To Acquire Available For Sale Securities Debt | $20.2M | $28.3M | $17.0M | ||||||||||||
| Increase Decrease In Accrued Expense And Other Liabilities | -$1.5M | -$1.3M | -$326.0K | ||||||||||||
| Payments Related To Tax Withholding For Share Based Compensation | $344.0K | $166.0K | |||||||||||||
| Payments Of Stock Issuance Costs | $85.0K | ||||||||||||||
| Proceeds From Issuance Of Private Placement | |||||||||||||||
| Proceeds From Issuance Of Warrants |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 38.5M | 33.8M | 22.1M | 4.1M | 1.7M |
| Weighted Average Number Of Diluted Shares Outstanding | 38.5M | 33.8M | 22.1M | 4.1M | 1.7M |
| Earnings Per Share Diluted | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 |
| Earnings Per Share Basic | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 |
| Common Stock Shares Outstanding | 31.6M | 31.2M | 22.5M | 21.9M | 1.8M |
| Common Stock Shares Issued | 31.6M | 31.2M | 22.5M | 21.9M | 1.8M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 40.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Restricted Stock Value Shares Issued Net Of Tax Withholdings | -750.0K | -2.5M | -1.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 38.6M | 38.5M | 38.4M | 38.1M | 36.1M | 22.6M | 22.1M | 22.0M | 21.9M | 1.8M | 1.8M | 1.8M | 1.8M |
| Weighted Average Number Of Diluted Shares Outstanding | 38.6M | 38.5M | 38.4M | 38.1M | 36.1M | 22.6M | 22.1M | 22.0M | 21.9M | 1.8M | 1.8M | 1.8M | 1.8M |
| Earnings Per Share Diluted | $-0.47 | $-0.55 | $-0.51 | $-0.59 | $-0.52 | $-0.73 | $-0.66 | $-0.63 | $-0.58 | $-5.17 | $-3.29 | $-4.08 | $-1.38 |
| Earnings Per Share Basic | $-0.47 | $-0.55 | $-0.51 | $-0.59 | $-0.52 | $-0.73 | $-0.66 | $-0.63 | $-0.58 | $-5.17 | $-3.29 | $-4.08 | $-1.38 |
| Common Stock Shares Outstanding | 31.5M | 31.4M | 31.4M | 31.1M | 31.0M | 22.6M | 22.1M | 22.1M | 21.9M | 1.8M | |||
| Common Stock Shares Issued | 31.5M | 31.4M | 31.4M | 31.1M | 31.0M | 22.6M | 22.1M | 22.1M | 21.9M | 1.8M | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 40.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Restricted Stock Value Shares Issued Net Of Tax Withholdings | -117.0K | -97.0K | -344.0K | -1.2M | -510.0K | -166.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Depreciation | $1.4M | $1.0M | $536.0K | $364.0K | $37.0K |
| Stock Issued During Period Value Stock Options Exercised | $1.0K | $90.0K | $775.0K | $24.0K | $1.0K |
| Additional Paid In Capital | $387.3M | $373.3M | $237.7M | $226.6M | $1.1M |
| Stock Issued During Period Shares Stock Options Exercised | 225.00 | 30.9K | 292.4K | 25.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation | $300.0K | $300.0K | $311.0K | $300.0K | $200.0K | $224.0K | $100.0K | $100.0K | $125.0K | $100.0K | $100.0K | $45.0K | $9.0K |
| Stock Issued During Period Value Stock Options Exercised | $1.0K | $11.0K | $79.0K | $78.0K | $379.0K | $24.0K | $1.0K | ||||||
| Additional Paid In Capital | $384.4M | $380.6M | $376.7M | $370.2M | $367.8M | $240.9M | $235.6M | $232.3M | $229.2M | $1.6M | |||
| Stock Issued During Period Shares Stock Options Exercised | 225.00 | 20.3K | 232.00 |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.